Drug research

ACP-204

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as ACP-204 Tartrate

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisNCT07029581	ACAD	Phase 2	Recruiting	2028-02Estimated
ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673	ACAD	Phase 2, Phase 3	Recruiting	2028-01Estimated
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisNCT07095465	ACAD	Phase 3	Enrolling by invitation	2029-02Estimated
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyNCT06194799	ACAD	Phase 3	Enrolling by invitation	2029-04Estimated

ACADRecruitingPrimary completion: 2028-02 · Estimated

Trial details

ACADRecruitingPrimary completion: 2028-01 · Estimated

Trial details

ACADEnrolling by invitationPrimary completion: 2029-02 · Estimated

Trial details

ACADEnrolling by invitationPrimary completion: 2029-04 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.